These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. Grimstein M; Yang Y; Zhang X; Grillo J; Huang SM; Zineh I; Wang Y J Pharm Sci; 2019 Jan; 108(1):21-25. PubMed ID: 30385284 [TBL] [Abstract][Full Text] [Related]
4. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling. Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691 [TBL] [Abstract][Full Text] [Related]
5. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling. Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249 [TBL] [Abstract][Full Text] [Related]
6. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Johnson TN; Rostami-Hodjegan A Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354 [TBL] [Abstract][Full Text] [Related]
7. A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development. Johnson TN; Small BG; Berglund EG; Rowland Yeo K CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):967-972. PubMed ID: 34288581 [TBL] [Abstract][Full Text] [Related]
8. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology. Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429 [TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic (PBPK) modeling in children. Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290 [TBL] [Abstract][Full Text] [Related]
11. Physiologically-based pharmacokinetic models for children: Starting to reach maturation? Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949 [TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs. Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657 [TBL] [Abstract][Full Text] [Related]
13. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics. Miyagi SJ; Long-Boyle JR Drug Metab Lett; 2015; 9(2):80-7. PubMed ID: 26031462 [TBL] [Abstract][Full Text] [Related]
14. Role of modeling and simulation in pediatric investigation plans. Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569 [TBL] [Abstract][Full Text] [Related]
15. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Leong R; Vieira ML; Zhao P; Mulugeta Y; Lee CS; Huang SM; Burckart GJ Clin Pharmacol Ther; 2012 May; 91(5):926-31. PubMed ID: 22472993 [TBL] [Abstract][Full Text] [Related]
16. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. Gaohua L; Miao X; Dou L Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134 [No Abstract] [Full Text] [Related]
17. Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. Vinks AA; Barrett JS J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S52-S59. PubMed ID: 34185897 [TBL] [Abstract][Full Text] [Related]
18. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future. Rowland Yeo K; Gil Berglund E; Chen Y Clin Pharmacol Ther; 2024 Sep; 116(3):563-576. PubMed ID: 38686708 [TBL] [Abstract][Full Text] [Related]
19. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Vinks AA; Emoto C; Fukuda T Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179 [TBL] [Abstract][Full Text] [Related]
20. Commentary on Fit-For-Purpose Models for Regulatory Applications. Wang Y; Huang SM J Pharm Sci; 2019 Jan; 108(1):18-20. PubMed ID: 30244011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]